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Major Health Problem
• Dramatic rise in rates of pharmaceutical 
opioid (PO) abuse and addiction 
• Many people suffer from chronic pain (CP)
• POs used increasingly to treat CP 
Prevalence and Incidence of Chronic Pain: WHO Study
4
11.2% for Seattle
PO Treatment Rate in CP Patients: Incidence
5
From:  Sullivan M, Epidemiology of Pain
Source: National Health Interview Survey
Suggests in 2005 that
(10.5/1000)*250M or 
~3M new patients 
received opioid
treatment for chronic 
non-cancer pain
OpA initiation rate of 
(3/75) = 4% for chronic 
non-cancer pain
PO Treatment Rate in CP Patients: Prevalence
6
From:  Sullivan M, Epidemiology of Pain
Source: National Health Interview Survey
Suggests in 2005 that
(35/1000)*250M or 
~9M under opioid
treatment for chronic
non-cancer pain
OpA treatment rate 
of (9/75) = 12%
for chronic non-cancer 
pain
Opioid Prescriptions and Patients (Verispan’s Total Patient Tracker)
Reflects total product uses for chronic and acute pain, includes patients on both.
From:  Governale L, FDA, CDER, Outpatient Drug Utilization Trends for Oxycodone Products, November, 2008
Governale L, FDA, CDER, Outpatient Drug Utilization Trends for Extended-Release Morphine Products, Nov., 2008
Governale L, Methadone Utilization in the U.S., 2002 – 2006, July, 2007
Source:  Verispan, LLC, SDI Vector One®: National (VONA) and SDI Total Patient Tracker
Prescriptions (TRX, millions)
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Long-acting
oxycodone ER 1.80 3.10 5.40 6.50 6.30 6.50 6.30 6.40 7.00 7.50
methadone 0.45 0.60 0.80 1.10 1.60 2.20 2.80 3.40 3.90 4.10
fentanyl 1.00 1.20 1.60 2.20 3.10 4.00 4.50 4.60 5.00 5.50
morphine ER 1.00 1.20 1.30 1.50 1.80 2.20 2.70 3.20 3.70 4.20
Short-acting
hydrocodone 60.00 68.00 76.00 80.00 85.00 90.00 95.00 105.00 110.00 120.00
oxycodone IR 14.00 15.90 16.60 18.50 20.50 23.50 25.00 27.50 31.00 34.70
hydromorphone 0.50 0.50 0.50 0.60 0.70 0.80 1.00 1.20 1.40 1.60
morphine IR 0.60 0.60 0.70 0.80 0.90 1.00 1.20 1.10 1.20 1.40
Patients (Millions)
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Long-acting
oxycodone ER 0.36 0.62 1.08 1.30 1.26 1.30 1.26 1.28 1.40 1.50
methadone 0.09 0.12 0.16 0.22 0.36 0.48 0.55 0.65 0.72 0.82
fentanyl 0.20 0.24 0.32 0.44 0.62 0.80 0.90 0.92 1.00 1.10
morphine ER 0.21 0.25 0.27 0.31 0.37 0.45 0.56 0.66 0.76 0.87
Short-acting
hydrocodone 22.82 25.87 28.91 30.43 32.33 34.24 36.14 39.94 41.84 45.65
oxycodone IR 5.33 6.05 6.31 7.04 7.80 8.94 9.51 10.46 11.79 13.20
hydromorphone 0.10 0.10 0.10 0.12 0.14 0.16 0.20 0.24 0.28 0.32
morphine IR 0.19 0.19 0.23 0.26 0.29 0.32 0.39 0.36 0.39 0.45
Adverse Outcomes
• Overdose incidents
• Emergency room visits
• Fatalities
• Overdose rate for individuals receiving 3 or more PO 
prescriptions within 90 days is 148 per 100,000 
person-years.
• Among those prescribed the highest dosage level 
(100mg/day or more), the annual OD rate was 1791 
per 100,000 person-years, representing  an “8.9-fold 
increase in overdose risk”  (p. 85) compared to those 
prescribed lower doses.
• Rate of overdose Mortality for these 
individuals is 17 per 100,000 person-years.
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Rate of Drug Overdose and Mortality among CP Patients
Dunn et al. (2010). Opioid prescriptions for chronic pain and overdose. 
Annals of Internal Medicine, 152(2), 85-92.
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Opioid Analgesic Poisoning Deaths NCHS/ NVSS
From: Warner, et 
al, “Increase in 
Fatal Poisonings 
Involving Opioid 
Analgesics in the 
United States, 
1999–2006”, 
NCHS Data Brief ■
No. 22 ■
September 2009
Includes
pain patients
and
nonmedical 
users
11
Medical Use Fraction of OpA Overdose Deaths
From: Aron J. Hall; Joseph E. Logan; Robin L. Toblin; et al. Patterns of Abuse Among Unintentional Pharmaceutical  Overdose Fatalities
JAMA. 2008;300(22):2613-2620 (doi:10.1001/jama.2008.802)
• Limited, state-level data  
without trends.   
• W. Virginia data in 2006
indicate that ~45% of 
decedents involving 
opioid analgesics had a 
prescription within the 
past year.
…using centralized prescription
records maintained by the
state’s prescription drug monitoring
program, we also were able to assess
the decedents’ prescription histories
in the year before their deaths.
What to do?
• Need effective interventions
• Need tools to identify policies to reduce 
opioid abuse, addiction, and overdose deaths.
• Would a system dynamics (SD) model meet 
this need?
– SD model structure features stocks and flows
– Auxiliary variables, equations, parameters


MU Add/Switch Rates to Long-Acting Rx Opioid 
oxycodone ER
• ~81% of new Rx dispensed to 
those had previous Rx for ER 
oxycodone product within past 
3 months
• ~6% had no previous Rx
• ~14% of new Rx switched or 
added-on from another pain 
therapy product, including 
other long-acting opioids
*3 month look-back period
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From:  Governale L, FDA, CDER, Outpatient Drug Utilization Trends for Oxycodone Products, November, 2008
Source:  Verispan, LLC, SDI Vector One®: National (VONA))
SA, LA, and SA+LA Utilization Pattern (White Study)
16
From: White AG, et al, “Direct Costs of Opioid Abuse in an Insured Population in the United States,”
J Manag Care Pharm. 2005;11(6):469-79
(population ~2M covered by 16 employer health plans)
Are there other claims database analyses that can be used to validate the above splits?
MU OpA Dependence & Abuse
17


Prescribers concerned about the risk of abuse and addiction and 
possible regulatory action are likely to prescribe fewer opioids overall 
(Wolfert et al., 2010) and to more cautiously prescribe long-acting 
products (Potter et al., 2001)
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Parameter Value Support
All Cause Mortality Rate for Patients on Long-acting 0.012 Modeling Team Judgment
All Cause Mortality Rate for Patients on Short-acting 0.01 Panel Consensus
All Cause Mortality Rate for Patients with Dependence or 
Abuse
0.015 Panel Consensus
Average Long-acting Treatment Duration (in years) 7 Panel Consensus
Average Short-acting Treatment Duration (in years) 2 Panel Consensus
Base Rate for Adding or Switching 0.03 Extrapolation from outcome data: Verispan, LLC, SDI 
Vector One®: National (VONA; see Governale, 2007)
Base Rate of Treatment 0.25 Panel Consensus
Base Risk Factor 1.5 Modeling Team Judgment
New Chronic Pain Diagnosis Rate 0.112 WHO (World Health Organization; see Gureje et al., 
2001)
Overdose Mortality Rate for Patients Abusing Opioids 0.0015 Extrapolation from Heroin Research (see Fisher et al., 
2004)
Overdose Mortality Rate for Patients on Long-acting 0.0025 CONSORT study (Consortium to Study Opioid Risks 
and Trends; see Dunn et al., 2010)
Overdose Mortality Rate for Patients on Short-acting 0.00005 CONSORT study (Consortium to Study Opioid Risks 
and Trends; see Dunn et al., 2010)
Rate of Addiction for Patients on Long-acting 0.05 Meta-Analyses (see Fishbain et al., 2008; Højsted & 
Sjøgren, 2007)
Rate of Addiction for Patients on Short-acting 0.02 VISN16 data (South Central Veterans Affairs Health 
Care Network; see Edlund et al., 2007)
Model Parameters
Baseline Results
Interventions
1. New highly tamper resistant LA formulation
– Reduces risk AND risk perception
2. Prescriber education program
– More cautious prescribing
3. Reduced rate of abuse/addiction
– But w/o changing prescriber baseline perceived 
risk  



An Alternative Metric 
• Deaths per 10,000 patients

Discussion
• System dynamics modeling has promise
– Tool for understanding the public health problem of 
PO-related mortality
– Tool for evaluating policy options and regulations to 
address the problem
• May be difficult to minimize negative outcomes 
without reduced CP patient access to PO 
treatment
• Important to choose the right metric(s)
• Need to consider multiple metrics
Study Strengths and Weaknesses
Systems perspective
Empirical support for 
many parameter values
Highlights need to 
carefully consider 
metrics
Recognizes need for 
policy makers to make 
value judgments to 
balance access to 
treatment and reducing 
adverse outcomes
Excludes acute pain
Assumes all pain 
patients are legitimate
Weak data support for 
some parameter values
Does not consider 
impacts of poly-drug use 
Does not consider 
impact of drug abuse 
treatment programs
Excludes alternative 
treatments for pain
Questions?
• Comments?
• Suggestions?
